PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Condition:   Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) Interventions:   Drug: Ipilimumab;   Drug: Osimertinib Sponsor:   University of Utah Not yet recruiting

Source: ClinicalTrials.gov - October 28, 2019 Category: Research Source Type: clinical trials